Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Epic American Credit and Bond Bubble Laboratory -- Ignore unavailable to you. Want to Upgrade?

To: NOW who wrote (52298)	2/1/2006 4:35:20 PM
From: GraceZ	Respond to of 110194

With VASO we will never know if the therapy would have helped a larger group since it's up against beta-blockers, statins, stents and by-pass surgury. We have no problem paying for the cure, but never for the early intervention that might have prevented that individual from winding up in the cath lab or OR. There is little doubt that a less toxic taxol has wide benefits. When you measure survival in months, delays in widening the reimbursement means many die waiting for it to be approved.